Jiangsu Hengrui Medicine
600276.SS
#508
Rank
NZ$65.46 B
Marketcap
$10.26
Share price
-0.27%
Change (1 day)
-0.28%
Change (1 year)
Jiangsu Hengrui Medicine Company Limited is a Chinese pharmaceutical company engaged in the R&D, manufacturing and sales of healthcare products, including antineoplastic drugs, angiomyocardiac drugs, drugs for surgery, contrast agents and antibiotics

Earnings for Jiangsu Hengrui Medicine (600276.SS)

Earnings in 2024 (TTM): NZ$1.35 B

According to Jiangsu Hengrui Medicine 's latest financial reports the company's current earnings (TTM) are NZ$1.32 B. In 2023 the company made an earning of NZ$1.06 B an increase over its 2022 earnings that were of NZ$0.95 B.The earnings displayed on this page is the company's Pretax Income.

Earnings history for Jiangsu Hengrui Medicine from 2002 to 2024

Annual earnings

Year Earnings Change
2024 (TTM) NZ$1.35 B26.77%
2023 NZ$1.06 B11.4%
2022 NZ$0.95 B-13.65%
2021 NZ$1.10 B-34.21%
2020 NZ$1.68 B15.95%
2019 NZ$1.45 B33.03%
2018 NZ$1.09 B20.89%
2017 NZ$0.90 B23.89%
2016 NZ$0.72 B11.21%
2015 NZ$0.65 B39.5%
2014 NZ$0.47 B20.61%
2013 NZ$0.38 B11.46%
2012 NZ$0.34 B29.7%
2011 NZ$0.26 B31.16%
2010 NZ$0.20 B27.92%
2009 NZ$0.16 B5.8%
2008 NZ$0.15 B79.95%
2007 NZ$84.43 M32.89%
2006 NZ$63.53 M38.19%
2005 NZ$45.98 M21.56%
2004 NZ$37.82 M13.95%
2003 NZ$33.19 M38.06%
2002 NZ$24.04 M